Acinetobacter baumannii bloodstream infections in a tertiary hospital: Antimicrobial resistance surveillance
AbstractBackground: Nosocomial bacteremia caused by Acinetobacter baumannii (AB) is of increasing concern in critically ill patients. There is a world-wide increase in the emergence of multidrug-resistant (MDR) AB to antimicrobials. Therefore we conducted this study to evaluate the resistance pattern of AB in patients with bacteremia. Methods: This is a retrospective study conducted in a tertiary hospital in Saudi Arabia. During the period from April 2008 till April 2010, data for AB isolated from blood were collected. Multidrug resistant AB was defined as resistance to three or more classes of antibiotics. Results: 191 isolates of AB were recovered from blood. The majority of cases were reported in surgical ICU (40.8%). The highest resistance rates to antimicrobials were reported for cefepime (73.8%) and piperacillin / tazobactam (72.3%), followed by ciprofloxacin (68%), and gentamicin (66%). Resistance rates were also high to imipenem (61.3%) and meropenem (60.7%). Low rates of resistance to colistin (0.5%) and to tigecycline (3.9%) were observed. 132 (69%) AB isolates were MDR and 104 (78.8%) of these MDR strains showed sensitivity only to colistin and tigecycline. Conclusion: Bacteremia due to AB was the highest in surgical ICU. The emergence of MDR AB is increasing and the resistance rates to carbapenems are alarming. Urgent measures are needed to slow development of MDR AB. We recommend encouraging clinicians for strict adherence to infection control policies, enhancement of ongoing antimicrobial stewardship program and restrictive use of recommended antibiotics according to susceptibility testing and local guidelines. In-house surveillance is needed for the detection of resistance rates particularly MDR AB.
Copyright conditions: Copyright on any research article in the International Journal of Infection Control (IJIC) is retained by the author(s). Authors grant IJIC permission to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified. IJIC conforms to the Creative Commons Attribution License (http://creativecommons.org) as terms and conditions of publishing research articles. In summary, anyone is free: • to copy, distribute, and display the work; • to make derivative works; • to make commercial use of the work; as long as: • the original author must be given credit; • for any reuse or distribution, it must be made clear to others what the license terms of this work are; • any of these conditions can be waived if the authors gives permission. Statutory fair use and other rights are in no way affected by the above. Authors' certification: In submitting a manuscript to IJIC, authors are requested to certify that: • They are authorized by their co-authors to enter into these arrangements. • They warrant, on behalf of themselves and their co-authors, that: o the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights; o they are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to IJIC are not in breach of any other obligation. If the law requires that the article be published in the public domain, they will notify IJIC at the time of submission; o the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy; o they have taken due care to ensure the integrity of the article.